Atlas Venture
VC Fund
Cambridge, United States
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
- Total investments:
- 438
- Last investment:
- Lead investor:
- 29%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Atlas Venture invests in
Stages Atlas Venture invests in
Countries Atlas Venture invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.5M–$92M
- Series B
- $8M–$115M
- Series C
- $6M–$95M
Investment Focus
Industry
- Biotechnology 97 (22%)
- Health Care 59 (13%)
- Therapeutics 50 (11%)
- Medical 42 (10%)
- Software 38 (9%)
Stage
- Series A 126 (29%)
- Series B 94 (21%)
- Series C 48 (11%)
- Seed 44 (10%)
- Funding Round 36 (8%)
Country
- United States 182 (42%)
- United Kingdom 20 (5%)
- Canada 5 (1%)
- France 5 (1%)
- Germany 5 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chelsea Place Johnson
Principal
|
Principal | Total investments: 2 | Find email | |
Ed Holson
Entrepreneur-in-Residence
|
Entrepreneur-in-Residence | Total investments: 0 | Find email | |
Jean-Francois Formela
Partner
|
Partner | Total investments: 21 | Find email | |
Kevin Bitterman
Partner
|
Partner | Total investments: 28 | Find email | |
Michael Gladstone
Principal
|
Principal | Total investments: 16 | Find email | |
| See all 20 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Triveni Bio
|
Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $65M / Series C / Jun 17, 2026 | |
Q32 Bio
|
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $55M / Post-IPO Equity / May 26, 2026 | |
Vima Therapeutics
|
Vima Therapeutics operates as a biotechnology company.Vima Therapeutics creates a new era in treatments for dystonia and related movement disorders. | $40M / Series A / Mar 11, 2026 | |
Kinaset Therapeutics
|
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M / Series B / Jan 10, 2026 | |
Diagonal Therapeutics
|
Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $125M / Series B / Jan 08, 2026 | |
Triana Biomedicines
|
Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M / Series B / Dec 03, 2025 | |
Lifordi Immunotherapeutics
|
Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders. | $42M / Venture - Series Unknown / Nov 19, 2025 | |
AAVantgarde Bio
|
AAVantgarde Bio is developing gene therapies for inherited retinal disorders. | $141M / Series B / Nov 03, 2025 | |
Affinia Therapeutics
|
Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle andcentral nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties. | $40M / Series C / Oct 07, 2025 | |
Renasant Bio
|
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments. | $54.5M / Seed / Jul 10, 2025 | |
| See all 438 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Atlas Venture invest in?
Atlas Venture invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 438 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Atlas Venture's check size?
Atlas Venture typically joins rounds of $3.5M–$92M at Series A, $8M–$115M at Series B and $6M–$95M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Atlas Venture participates in.
How do I contact Atlas Venture?
Public channels for Atlas Venture include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Atlas Venture?
The team at Atlas Venture includes Chelsea Place Johnson (Principal), Ed Holson (Entrepreneur-in-Residence) and Jean-Francois Formela (Partner), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
